Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 208 articles:
HTML format
Text format



Single Articles


    March 2017
  1. LIM JP, Shyamasundar S, Gunaratne J, Scully OJ, et al
    YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro.
    BMC Cancer. 2017;17:201.
    PubMed     Text format     Abstract available


  2. DODOVA RI, Mitkova AV, Dacheva DR, Hadjo LB, et al
    Erratum to: Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
    BMC Cancer. 2017;17:195.
    PubMed     Text format    


  3. HUANG Y, Burns DJ, Rich BE, MacNeil IA, et al
    Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
    BMC Cancer. 2017;17:199.
    PubMed     Text format     Abstract available


  4. DOS SANTOS AF, Terra LF, Wailemann RA, Oliveira TC, et al
    Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells.
    BMC Cancer. 2017;17:194.
    PubMed     Text format     Abstract available


  5. CHARAGHVANDI RK, van Asselen B, Philippens ME, Verkooijen HM, et al
    Redefining radiotherapy for early-stage breast cancer with single dose ablative treatment: a study protocol.
    BMC Cancer. 2017;17:181.
    PubMed     Text format     Abstract available


  6. KROZ M, Reif M, Glinz A, Berger B, et al
    Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive cohort design.
    BMC Cancer. 2017;17:166.
    PubMed     Text format     Abstract available


    February 2017
  7. INARI H, Suganuma N, Kawachi K, Yoshida T, et al
    Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
    BMC Cancer. 2017;17:160.
    PubMed     Text format     Abstract available


  8. MORRIS M, Woods LM, Bhaskaran K, Rachet B, et al
    Do pre-diagnosis primary care consultation patterns explain deprivation-specific differences in net survival among women with breast cancer? An examination of individually-linked data from the UK West Midlands cancer registry, national screening progr
    BMC Cancer. 2017;17:155.
    PubMed     Text format     Abstract available


  9. MCKINNON CM, Mellor H
    The tumor suppressor RhoBTB1 controls Golgi integrity and breast cancer cell invasion through METTL7B.
    BMC Cancer. 2017;17:145.
    PubMed     Text format     Abstract available


  10. SINN HP, Schneeweiss A, Keller M, Schlombs K, et al
    Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    BMC Cancer. 2017;17:124.
    PubMed     Text format     Abstract available


  11. EFFI AB, Aman NA, Koui BS, Koffi KD, et al
    Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
    BMC Cancer. 2017;17:115.
    PubMed     Text format     Abstract available


  12. JAISWAL R, Johnson MS, Pokharel D, Krishnan SR, et al
    Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion.
    BMC Cancer. 2017;17:104.
    PubMed     Text format     Abstract available


  13. WENGSTROM Y, Bolam KA, Mijwel S, Sundberg CJ, et al
    Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy.
    BMC Cancer. 2017;17:100.
    PubMed     Text format     Abstract available


  14. BARBA M, Vici P, Pizzuti L, Di Lauro L, et al
    Body mass index modifies the relationship between gamma-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
    BMC Cancer. 2017;17:101.
    PubMed     Text format     Abstract available


    January 2017
  15. LAVENDER N, Yang J, Chen SC, Sai J, et al
    The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo.
    BMC Cancer. 2017;17:88.
    PubMed     Text format     Abstract available


  16. VIERKANT RA, Degnim AC, Radisky DC, Visscher DW, et al
    Mammographic breast density and risk of breast cancer in women with atypical hyperplasia: an observational cohort study from the Mayo Clinic Benign Breast Disease (BBD) cohort.
    BMC Cancer. 2017;17:84.
    PubMed     Text format     Abstract available


  17. AUGUSTIN LS, Libra M, Crispo A, Grimaldi M, et al
    Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial.
    BMC Cancer. 2017;17:69.
    PubMed     Text format     Abstract available


  18. VESUNA F, Bergman Y, Raman V
    Genomic pathways modulated by Twist in breast cancer.
    BMC Cancer. 2017;17:52.
    PubMed     Text format     Abstract available


  19. NANDI P, Girish GV, Majumder M, Xin X, et al
    PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells.
    BMC Cancer. 2017;17:11.
    PubMed     Text format     Abstract available


  20. SORENSEN KM, Meldgaard T, Melchjorsen CJ, Fridriksdottir AJ, et al
    Upregulation of Mrps18a in breast cancer identified by selecting phage antibody libraries on breast tissue sections.
    BMC Cancer. 2017;17:19.
    PubMed     Text format     Abstract available


  21. SHACHAR SS, Mashiach T, Fried G, Drumea K, et al
    Biopsy of breast cancer metastases: patient characteristics and survival.
    BMC Cancer. 2017;17:7.
    PubMed     Text format     Abstract available


    December 2016
  22. SCHULER-TOPRAK S, Haring J, Inwald EC, Moehle C, et al
    Agonists and knockdown of estrogen receptor beta differentially affect invasion of triple-negative breast cancer cells in vitro.
    BMC Cancer. 2016;16:951.
    PubMed     Text format     Abstract available


  23. GIBBONS A, Groarke A, Sweeney K
    Predicting general and cancer-related distress in women with newly diagnosed breast cancer.
    BMC Cancer. 2016;16:935.
    PubMed     Text format     Abstract available


  24. LIN FP, Pokorny A, Teng C, Dear R, et al
    Computational prediction of multidisciplinary team decision-making for adjuvant breast cancer drug therapies: a machine learning approach.
    BMC Cancer. 2016;16:929.
    PubMed     Text format     Abstract available


    November 2016
  25. HONG R, Ma F, Zhang W, Yu X, et al
    Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    BMC Cancer. 2016;16:925.
    PubMed     Text format    


  26. ARPINO G, Pensabene M, Condello C, Ruocco R, et al
    Tumor characteristics and prognosis in familial breast cancer.
    BMC Cancer. 2016;16:924.
    PubMed     Text format     Abstract available


  27. VANKLOMPENBERG MK, Bedalov CO, Soto KF, Prosperi JR, et al
    Erratum to: APC selectively mediates response to chemotherapeutic agents in breast cancer.
    BMC Cancer. 2016;16:921.
    PubMed     Text format    


  28. ATEMA V, van Leeuwen M, Oldenburg HS, Retel V, et al
    Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors.
    BMC Cancer. 2016;16:920.
    PubMed     Text format     Abstract available


  29. KOSALOGLU Z, Bitzer J, Halama N, Huang Z, et al
    In silico SNP analysis of the breast cancer antigen NY-BR-1.
    BMC Cancer. 2016;16:901.
    PubMed     Text format     Abstract available


  30. MAGNUSSON K, Gremel G, Ryden L, Ponten V, et al
    ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
    BMC Cancer. 2016;16:904.
    PubMed     Text format     Abstract available


  31. WANG Y, Chen L, Wu Z, Wang M, et al
    miR-124-3p functions as a tumor suppressor in breast cancer by targeting CBL.
    BMC Cancer. 2016;16:826.
    PubMed     Text format     Abstract available


  32. CHEN J, Shin VY, Siu MT, Ho JC, et al
    miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
    BMC Cancer. 2016;16:887.
    PubMed     Text format     Abstract available


  33. GEIGER P, Mayer B, Wiest I, Schulze S, et al
    Binding of galectin-1 to breast cancer cells MCF7 induces apoptosis and inhibition of proliferation in vitro in a 2D- and 3D- cell culture model.
    BMC Cancer. 2016;16:870.
    PubMed     Text format     Abstract available


  34. MONROY-CISNEROS K, Esparza-Romero J, Valencia ME, Guevara-Torres AG, et al
    Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients.
    BMC Cancer. 2016;16:860.
    PubMed     Text format     Abstract available


  35. BLODT S, Mittring N, Schutzler L, Fischer F, et al
    A consultation training program for physicians for communication about complementary medicine with breast cancer patients: a prospective, multi-center, cluster-randomized, mixed-method pilot study.
    BMC Cancer. 2016;16:843.
    PubMed     Text format     Abstract available


  36. WINSLOW S, Lindquist KE, Edsjo A, Larsson C, et al
    The expression pattern of matrix-producing tumor stroma is of prognostic importance in breast cancer.
    BMC Cancer. 2016;16:841.
    PubMed     Text format     Abstract available


  37. SHEN CC, Hu LY, Yang AC, Chiang YY, et al
    Risk of uterine, ovarian and breast cancer following pelvic inflammatory disease: a nationwide population-based retrospective cohort study.
    BMC Cancer. 2016;16:839.
    PubMed     Text format     Abstract available


  38. MASARWAH A, Auvinen P, Sudah M, Dabravolskaite V, et al
    Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
    BMC Cancer. 2016;16:833.
    PubMed     Text format     Abstract available


    October 2016
  39. REEVES MM, Terranova CO, Erickson JM, Job JR, et al
    Living well after breast cancer randomized controlled trial protocol: evaluating a telephone-delivered weight loss intervention versus usual care in women following treatment for breast cancer.
    BMC Cancer. 2016;16:830.
    PubMed     Text format     Abstract available


  40. WOLF B, Goebel G, Hackl H, Fiegl H, et al
    Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients.
    BMC Cancer. 2016;16:821.
    PubMed     Text format     Abstract available


  41. WOODHEAD C, Cunningham R, Ashworth M, Barley E, et al
    Cervical and breast cancer screening uptake among women with serious mental illness: a data linkage study.
    BMC Cancer. 2016;16:819.
    PubMed     Text format     Abstract available


  42. MIAO H, Hartman M, Verkooijen HM, Taib NA, et al
    Validation of the CancerMath prognostic tool for breast cancer in Southeast Asia.
    BMC Cancer. 2016;16:820.
    PubMed     Text format     Abstract available


  43. ZHOU Y, Lin S, Tseng KF, Han K, et al
    Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.
    BMC Cancer. 2016;16:818.
    PubMed     Text format     Abstract available


  44. BECKER MA, Hou X, Tienchaianada P, Haines BB, et al
    Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
    BMC Cancer. 2016;16:814.
    PubMed     Text format     Abstract available


  45. YU Y, Cui N, Li HY, Wu YM, et al
    Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer: retrospective comparative evaluation of clinically axillary lymph node positive and negative patients, including those with axillary lymph node metastases confirmed by fine n
    BMC Cancer. 2016;16:808.
    PubMed     Text format     Abstract available


  46. NEKULOVA M, Holcakova J, Gu X, Hrabal V, et al
    DeltaNp63alpha expression induces loss of cell adhesion in triple-negative breast cancer cells.
    BMC Cancer. 2016;16:782.
    PubMed     Text format     Abstract available


  47. ROCHLITZ C, Bigler M, von Moos R, Bernhard J, et al
    SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase II
    BMC Cancer. 2016;16:780.
    PubMed     Text format     Abstract available


    February 2016
  48. NARENDRULA R, Mispel-Beyer K, Guo B, Parissenti AM, et al
    RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
    BMC Cancer. 2016;16:146.
    PubMed     Text format     Abstract available


  49. NOLAN RM, Adie SG, Marjanovic M, Chaney EJ, et al
    Intraoperative optical coherence tomography for assessing human lymph nodes for metastatic cancer.
    BMC Cancer. 2016;16:144.
    PubMed     Text format     Abstract available


    January 2016
  50. PARK HL, Ziogas A, Chang J, Desai B, et al
    Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers Study.
    BMC Cancer. 2016;16:14.
    PubMed     Text format     Abstract available


  51. SINILNIKOVA OM, Dondon MG, Eon-Marchais S, Damiola F, et al
    GENESIS: a French national resource to study the missing heritability of breast cancer.
    BMC Cancer. 2016;16:13.
    PubMed     Text format     Abstract available


  52. VAD-NIELSEN J, Jakobsen KR, Daugaard TF, Thomsen R, et al
    Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1alpha down-regulation in metastatic cells.
    BMC Cancer. 2016;16:32.
    PubMed     Text format     Abstract available


  53. YANG SF, Hou MF, Chen FM, Ou-Yang F, et al
    Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy.
    BMC Cancer. 2016;16:20.
    PubMed     Text format     Abstract available


  54. JANDU H, Aluzaite K, Fogh L, Thrane SW, et al
    Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    BMC Cancer. 2016;16:34.
    PubMed     Text format     Abstract available


  55. KIM MJ, Su MY, Yu HJ, Chen JH, et al
    US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.
    BMC Cancer. 2016;16:50.
    PubMed     Text format     Abstract available


  56. DENU RA, Zasadil LM, Kanugh C, Laffin J, et al
    Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer.
    BMC Cancer. 2016;16:47.
    PubMed     Text format     Abstract available


  57. THALLINGER C, Lang I, Kuhar CG, Bartsch R, et al
    Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
    BMC Cancer. 2016;16:121.
    PubMed     Text format     Abstract available


  58. BHANDARI PM, Thapa K, Dhakal S, Bhochhibhoya S, et al
    Breast cancer literacy among higher secondary students: results from a cross-sectional study in Western Nepal.
    BMC Cancer. 2016;16:119.
    PubMed     Text format     Abstract available


  59. PROSKURINA AS, Gvozdeva TS, Alyamkina EA, Dolgova EV, et al
    Erratum to: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer.
    BMC Cancer. 2016;16:117.
    PubMed     Text format    


  60. HE PS, Li F, Li GH, Guo C, et al
    The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review.
    BMC Cancer. 2016;16:107.
    PubMed     Text format     Abstract available


  61. SENEVIRATNE S, Lawrenson R, Harvey V, Ramsaroop R, et al
    Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology.
    BMC Cancer. 2016;16:129.
    PubMed     Text format     Abstract available


  62. MEGO M, Cholujova D, Minarik G, Sedlackova T, et al
    CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.
    BMC Cancer. 2016;16:127.
    PubMed     Text format     Abstract available


  63. REIJM EA, Sieuwerts AM, Smid M, Vries JB, et al
    An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
    BMC Cancer. 2016;16:123.
    PubMed     Text format     Abstract available


  64. BOCCIA R, O'Boyle E, Cooper W
    Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy.
    BMC Cancer. 2016;16:166.
    PubMed     Text format     Abstract available


  65. MAROUF C, Gohler S, Filho MI, Hajji O, et al
    Analysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.
    BMC Cancer. 2016;16:165.
    PubMed     Text format     Abstract available


  66. BAMODU OA, Huang WC, Lee WH, Wu A, et al
    Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    BMC Cancer. 2016;16:160.
    PubMed     Text format     Abstract available


  67. RING BZ, Hout DR, Morris SW, Lawrence K, et al
    Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
    BMC Cancer. 2016;16:143.
    PubMed     Text format     Abstract available


  68. NILSSON G, Kannius-Janson M
    Forkhead Box F1 promotes breast cancer cell migration by upregulating lysyl oxidase and suppressing Smad2/3 signaling.
    BMC Cancer. 2016;16:142.
    PubMed     Text format     Abstract available


  69. KIM JY, Jung HH, Do IG, Bae S, et al
    Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
    BMC Cancer. 2016;16:138.
    PubMed     Text format     Abstract available


  70. HUANG X, Borgstrom B, Kempengren S, Persson L, et al
    Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.
    BMC Cancer. 2016;16:145.
    PubMed     Text format     Abstract available


  71. SAWE RT, Kerper M, Badve S, Li J, et al
    Aggressive breast cancer in western Kenya has early onset, high proliferation, and immune cell infiltration.
    BMC Cancer. 2016;16:204.
    PubMed     Text format     Abstract available


  72. LYONS EJ, Baranowski T, Basen-Engquist KM, Lewis ZH, et al
    Testing the effects of narrative and play on physical activity among breast cancer survivors using mobile apps: study protocol for a randomized controlled trial.
    BMC Cancer. 2016;16:202.
    PubMed     Text format     Abstract available


  73. KIM E, Tunset HM, Cebulla J, Vettukattil R, et al
    Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.
    BMC Cancer. 2016;16:191.
    PubMed     Text format     Abstract available


  74. ANDRADE SS, Gouvea IE, Silva MC, Castro ED, et al
    Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer.
    BMC Cancer. 2016;16:173.
    PubMed     Text format     Abstract available


  75. CAI S, Geng S, Jin F, Liu J, et al
    POU5F1/Oct-4 expression in breast cancer tissue is significantly associated with non-sentinel lymph node metastasis.
    BMC Cancer. 2016;16:175.
    PubMed     Text format     Abstract available


  76. MEZENCEV R, Matyunina LV, Jabbari N, McDonald JF, et al
    Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity.
    BMC Cancer. 2016;16:236.
    PubMed     Text format     Abstract available


  77. LAHART IM, Metsios GS, Nevill AM, Kitas GD, et al
    Randomised controlled trial of a home-based physical activity intervention in breast cancer survivors.
    BMC Cancer. 2016;16:234.
    PubMed     Text format     Abstract available


  78. UENO T, Saji S, Sugimoto M, Masuda N, et al
    Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.
    BMC Cancer. 2016;16:230.
    PubMed     Text format     Abstract available


  79. ALVAREZ C, Aravena A, Tapia T, Rozenblum E, et al
    Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
    BMC Cancer. 2016;16:219.
    PubMed     Text format     Abstract available


  80. CONSTANTINOU P, Dray-Spira R, Menvielle G
    Cervical and breast cancer screening participation for women with chronic conditions in France: results from a national health survey.
    BMC Cancer. 2016;16:255.
    PubMed     Text format     Abstract available


  81. SIMONSSON M, Veerla S, Markkula A, Rose C, et al
    CYP1A2 - a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    BMC Cancer. 2016;16:256.
    PubMed     Text format     Abstract available


  82. RING BZ, Hout DR, Morris SW, Lawrence K, et al
    Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
    BMC Cancer. 2016;16:275.
    PubMed     Text format    


  83. BRODSKY AS, Xiong J, Yang D, Schorl C, et al
    Identification of stromal ColXalpha1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.
    BMC Cancer. 2016;16:274.
    PubMed     Text format     Abstract available


  84. KOPP TI, Jensen DM, Ravn-Haren G, Cohen A, et al
    Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlle
    BMC Cancer. 2016;16:283.
    PubMed     Text format     Abstract available


  85. DIESSNER J, Wischnewsky M, Stuber T, Stein R, et al
    Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
    BMC Cancer. 2016;16:307.
    PubMed     Text format     Abstract available


  86. HENDERSON SL, Teft WA, Kim RB
    Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFalpha biologic for ulcerative colitis: a case report.
    BMC Cancer. 2016;16:304.
    PubMed     Text format     Abstract available


  87. SOMASUNDARAM V, Hemalatha SK, Pal K, Sinha S, et al
    Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    BMC Cancer. 2016;16:336.
    PubMed     Text format     Abstract available


  88. MOSLEHI R, Freedman E, Zeinomar N, Veneroso C, et al
    Importance of hereditary and selected environmental risk factors in the etiology of inflammatory breast cancer: a case-comparison study.
    BMC Cancer. 2016;16:334.
    PubMed     Text format     Abstract available


  89. BAZZI ZA, Lanoue D, El-Youssef M, Romagnuolo R, et al
    Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    BMC Cancer. 2016;16:328.
    PubMed     Text format     Abstract available


  90. CLARE SE, Gupta A, Choi M, Ranjan M, et al
    Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes.
    BMC Cancer. 2016;16:326.
    PubMed     Text format     Abstract available


  91. CHEN Y, Chen K, Xiao X, Nie Y, et al
    Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study.
    BMC Cancer. 2016;16:320.
    PubMed     Text format     Abstract available


  92. KIM HA, Ahn SH, Nam SJ, Park S, et al
    The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress
    BMC Cancer. 2016;16:319.
    PubMed     Text format     Abstract available


  93. ARROSPIDE A, Rue M, van Ravesteyn NT, Comas M, et al
    Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis.
    BMC Cancer. 2016;16:344.
    PubMed     Text format     Abstract available


  94. GANGADHARA S, Smith C, Barrett-Lee P, Hiscox S, et al
    3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.
    BMC Cancer. 2016;16:345.
    PubMed     Text format     Abstract available


  95. CAO Y, Feng Y, Zhang Y, Zhu X, et al
    L-Arginine supplementation inhibits the growth of breast cancer by enhancing innate and adaptive immune responses mediated by suppression of MDSCs in vivo.
    BMC Cancer. 2016;16:343.
    PubMed     Text format     Abstract available


  96. REIMER T, Kempert S, Gerber B, Thiesen HJ, et al
    SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study.
    BMC Cancer. 2016;16:337.
    PubMed     Text format     Abstract available


  97. GOLUBNITSCHAJA O, Yeghiazaryan K, Stricker H, Trog D, et al
    Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours.
    BMC Cancer. 2016;16:357.
    PubMed     Text format     Abstract available


  98. MAGHOUS A, Rais F, Ahid S, Benhmidou N, et al
    Factors influencing diagnosis delay of advanced breast cancer in Moroccan women.
    BMC Cancer. 2016;16:356.
    PubMed     Text format     Abstract available


  99. MILLER K, Cortes J, Hurvitz SA, Krop IE, et al
    HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer.
    BMC Cancer. 2016;16:352.
    PubMed     Text format     Abstract available


  100. BOUCHARD G, Therriault H, Geha S, Berube-Lauziere Y, et al
    Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
    BMC Cancer. 2016;16:361.
    PubMed     Text format     Abstract available


  101. JANSSON S, Bendahl PO, Larsson AM, Aaltonen KE, et al
    Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    BMC Cancer. 2016;16:433.
    PubMed     Text format     Abstract available


  102. LAIBLE M, Schlombs K, Kaiser K, Veltrup E, et al
    Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    BMC Cancer. 2016;16:398.
    PubMed     Text format     Abstract available


  103. DAVIES EA, Coupland VH, Dixon S, Mokbel K, et al
    Comparing the case mix and survival of women receiving breast cancer care from one private provider with other London women with breast cancer: pilot data exchange and analyses.
    BMC Cancer. 2016;16:421.
    PubMed     Text format     Abstract available


  104. KOBAYASHI T, Tomomatsu J, Fukada I, Shibayama T, et al
    Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study.
    BMC Cancer. 2016;16:404.
    PubMed     Text format     Abstract available


  105. LEE ES, Han W, Kim MK, Kim J, et al
    Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer.
    BMC Cancer. 2016;16:430.
    PubMed     Text format     Abstract available


  106. JUECKSTOCK J, Rack B, Friedl TW, Scholz C, et al
    Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    BMC Cancer. 2016;16:401.
    PubMed     Text format     Abstract available


  107. WINKEL RR, von Euler-Chelpin M, Nielsen M, Petersen K, et al
    Mammographic density and structural features can individually and jointly contribute to breast cancer risk assessment in mammography screening: a case-control study.
    BMC Cancer. 2016;16:414.
    PubMed     Text format     Abstract available


  108. YANG M, Ma B, Shao H, Clark AM, et al
    Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells.
    BMC Cancer. 2016;16:419.
    PubMed     Text format     Abstract available


  109. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
    Serum HER2 extra-cellular domain, S100ss and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
    BMC Cancer. 2016;16:428.
    PubMed     Text format     Abstract available


  110. KANGASPESKA S, Hultsch S, Jaiswal A, Edgren H, et al
    Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
    BMC Cancer. 2016;16:378.
    PubMed     Text format     Abstract available


  111. GARGIULO P, Pensabene M, Milano M, Arpino G, et al
    Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    BMC Cancer. 2016;16:375.
    PubMed     Text format     Abstract available


  112. FLORES-PEREZ A, Marchat LA, Rodriguez-Cuevas S, Bautista VP, et al
    Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells.
    BMC Cancer. 2016;16:379.
    PubMed     Text format     Abstract available


  113. YU X, Hu G, Zhang Z, Qiu F, et al
    Retrospective and comparative analysis of (99m)Tc-Sestamibi breast specific gamma imaging versus mammography, ultrasound, and magnetic resonance imaging for the detection of breast cancer in Chinese women.
    BMC Cancer. 2016;16:450.
    PubMed     Text format     Abstract available


  114. ZDUNIAK K, Agrawal A, Agrawal S, Hossain MM, et al
    Osteopontin splice variants are differential predictors of breast cancer treatment responses.
    BMC Cancer. 2016;16:441.
    PubMed     Text format     Abstract available


  115. DENG W, Wang Y, Gu L, Duan B, et al
    MICAL1 controls cell invasive phenotype via regulating oxidative stress in breast cancer cells.
    BMC Cancer. 2016;16:489.
    PubMed     Text format     Abstract available


  116. MARTINEZ JA, Chalasani P, Thomson CA, Roe D, et al
    Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol.
    BMC Cancer. 2016;16:500.
    PubMed     Text format     Abstract available


  117. LUI A, New J, Ogony J, Thomas S, et al
    Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells.
    BMC Cancer. 2016;16:487.
    PubMed     Text format     Abstract available


  118. COURNEYA KS, McNeely ML, Culos-Reed SN, Vallance JK, et al
    The Alberta Moving Beyond Breast Cancer (AMBER) Cohort Study: Recruitment, Baseline Assessment, and Description of the First 500 Participants.
    BMC Cancer. 2016;16:481.
    PubMed     Text format     Abstract available


  119. CHEN BB, Lu YS, Lin CH, Chen WW, et al
    A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.
    BMC Cancer. 2016;16:466.
    PubMed     Text format     Abstract available


  120. STEIN RG, Wollschlager D, Kreienberg R, Janni W, et al
    The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients.
    BMC Cancer. 2016;16:459.
    PubMed     Text format     Abstract available


  121. COCKBURN JG, Hallett RM, Gillgrass AE, Dias KN, et al
    The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.
    BMC Cancer. 2016;16:555.
    PubMed     Text format     Abstract available


  122. AL-HOWAIL HA, Hakami HA, Al-Otaibi B, Al-Mazrou A, et al
    PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
    BMC Cancer. 2016;16:540.
    PubMed     Text format     Abstract available


  123. VILSMAIER T, Rack B, Janni W, Jeschke U, et al
    Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment.
    BMC Cancer. 2016;16:547.
    PubMed     Text format     Abstract available


  124. BAUMANN J, Wong J, Sun Y, Conklin DS, et al
    Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells.
    BMC Cancer. 2016;16:551.
    PubMed     Text format     Abstract available


  125. WU LA, Kuo WH, Chen CY, Tsai YS, et al
    The association of infrared imaging findings of the breast with prognosis in breast cancer patients: an observational cohort study.
    BMC Cancer. 2016;16:541.
    PubMed     Text format     Abstract available


  126. ZHU J, Zhuang T, Yang H, Li X, et al
    Atypical ubiquitin ligase RNF31: the nuclear factor modulator in breast cancer progression.
    BMC Cancer. 2016;16:538.
    PubMed     Text format     Abstract available


  127. AKTAS B, Kasimir-Bauer S, Muller V, Janni W, et al
    Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    BMC Cancer. 2016;16:522.
    PubMed     Text format     Abstract available


  128. ZHANG S, Li L, Wang T, Bian L, et al
    Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    BMC Cancer. 2016;16:526.
    PubMed     Text format     Abstract available


  129. PLOOS VAN AMSTEL FK, Prins JB, van der Graaf WT, Peters ME, et al
    The effectiveness of a nurse-led intervention with the distress thermometer for patients treated with curative intent for breast cancer: design of a randomized controlled trial.
    BMC Cancer. 2016;16:520.
    PubMed     Text format     Abstract available


  130. VAN HELMONDT SJ, van der Lee ML, de Vries J
    Study protocol of the CAREST-trial: a randomised controlled trial on the (cost-) effectiveness of a CBT-based online self-help training for fear of cancer recurrence in women with curatively treated breast cancer.
    BMC Cancer. 2016;16:527.
    PubMed     Text format     Abstract available


  131. BLOOMQUIST K, Hayes S, Adamsen L, Moller T, et al
    A randomized cross-over trial to detect differences in arm volume after low- and heavy-load resistance exercise among patients receiving adjuvant chemotherapy for breast cancer at risk for arm lymphedema: study protocol.
    BMC Cancer. 2016;16:517.
    PubMed     Text format     Abstract available


  132. YANG Y, Im SA, Keam B, Lee KH, et al
    Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses.
    BMC Cancer. 2016;16:515.
    PubMed     Text format     Abstract available


  133. BERNAL-ESTEVEZ D, Sanchez R, Tejada RE, Parra-Lopez C, et al
    Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.
    BMC Cancer. 2016;16:591.
    PubMed     Text format     Abstract available


  134. CHOI SK, Kim HS, Jin T, Hwang EH, et al
    Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    BMC Cancer. 2016;16:570.
    PubMed     Text format     Abstract available


  135. SHE QB, Gruvberger-Saal SK, Maurer M, Chen Y, et al
    Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    BMC Cancer. 2016;16:587.
    PubMed     Text format     Abstract available


  136. MARTINEZ L, Thames E, Kim J, Chaudhuri G, et al
    Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis.
    BMC Cancer. 2016;16:559.
    PubMed     Text format     Abstract available


  137. KUHLMANN JD, Bankfalvi A, Schmid KW, Callies R, et al
    Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.
    BMC Cancer. 2016;16:618.
    PubMed     Text format     Abstract available


  138. HUBER MC, Mall R, Braselmann H, Feuchtinger A, et al
    uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    BMC Cancer. 2016;16:615.
    PubMed     Text format     Abstract available


  139. JIN X, Jiang YZ, Chen S, Yu KD, et al
    A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer.
    BMC Cancer. 2016;16:606.
    PubMed     Text format     Abstract available


  140. MC MENAMIN UC, Murray LJ, Hughes CM, Cardwell CR, et al
    Statin use and breast cancer survival: a nationwide cohort study in Scotland.
    BMC Cancer. 2016;16:600.
    PubMed     Text format     Abstract available


  141. MCNEELY ML, Campbell KL, Webster M, Kuusk U, et al
    Efficacy of night-time compression for breast cancer related lymphedema (LYNC): protocol for a multi-centre, randomized controlled efficacy trial.
    BMC Cancer. 2016;16:601.
    PubMed     Text format     Abstract available


  142. REZANIA S, Kammerer S, Li C, Steinecker-Frohnwieser B, et al
    Overexpression of KCNJ3 gene splice variants affects vital parameters of the malignant breast cancer cell line MCF-7 in an opposing manner.
    BMC Cancer. 2016;16:628.
    PubMed     Text format     Abstract available


  143. RUDOLPH M, Anzeneder T, Schulz A, Beckmann G, et al
    AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
    BMC Cancer. 2016;16:622.
    PubMed     Text format     Abstract available


  144. RASHID MU, Muhammad N, Bajwa S, Faisal S, et al
    High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    BMC Cancer. 2016;16:673.
    PubMed     Text format     Abstract available


  145. KRSTIC M, Macmillan CD, Leong HS, Clifford AG, et al
    The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
    BMC Cancer. 2016;16:671.
    PubMed     Text format     Abstract available


  146. TAKAHASHI Y, Uruga H, Fujii T, Mochizuki S, et al
    Antemortem diagnosis of pulmonary tumor thrombotic microangiopathy in a patient with recurrent breast cancer: a case report.
    BMC Cancer. 2016;16:666.
    PubMed     Text format     Abstract available


  147. DIERSSEN-SOTOS T, Gomez-Acebo I, de Pedro M, Perez-Gomez B, et al
    Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) study.
    BMC Cancer. 2016;16:660.
    PubMed     Text format     Abstract available


  148. GUERRA E, Cimadamore A, Simeone P, Vacca G, et al
    p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.
    BMC Cancer. 2016;16:649.
    PubMed     Text format     Abstract available


  149. PROSKURINA AS, Gvozdeva TS, Potter EA, Dolgova EV, et al
    Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen.
    BMC Cancer. 2016;16:651.
    PubMed     Text format     Abstract available


  150. GREGOIRE JM, Fleury L, Salazar-Cardozo C, Alby F, et al
    Identification of epigenetic factors regulating the mesenchyme to epithelium transition by RNA interference screening in breast cancer cells.
    BMC Cancer. 2016;16:700.
    PubMed     Text format     Abstract available


  151. CHEN CY, Yang CY, Chen YC, Shih CW, et al
    Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer.
    BMC Cancer. 2016;16:697.
    PubMed     Text format     Abstract available


  152. ZHOU K, Wang D, He X, Huo L, et al
    Effectiveness of a multimodal standard nursing program on health-related quality of life in Chinese mainland female patients with breast cancer: protocol for a single-blind cluster randomized controlled trial.
    BMC Cancer. 2016;16:698.
    PubMed     Text format     Abstract available


  153. SHOU J, Zhang Z, Lai Y, Chen Z, et al
    Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
    BMC Cancer. 2016;16:687.
    PubMed     Text format     Abstract available


  154. MENESES-ECHAVEZ JF, Jimenez EG, Rio-Valle JS, Correa-Bautista JE, et al
    The insulin-like growth factor system is modulated by exercise in breast cancer survivors: a systematic review and meta-analysis.
    BMC Cancer. 2016;16:682.
    PubMed     Text format     Abstract available


  155. KUBECEK O, Soukup T, Paulik A, Kopecky J, et al
    Dermatomyositis with anti-TIF-1gamma antibodies as a presenting symptom of underlying triple-negative breast cancer: a case report.
    BMC Cancer. 2016;16:684.
    PubMed     Text format     Abstract available


  156. MIN L, Zhang C, Ma R, Li X, et al
    Overexpression of synuclein-gamma predicts lack of benefit from radiotherapy for breast cancer patients.
    BMC Cancer. 2016;16:717.
    PubMed     Text format     Abstract available


  157. HENNIGS A, Riedel F, Gondos A, Sinn P, et al
    Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study.
    BMC Cancer. 2016;16:734.
    PubMed     Text format     Abstract available


  158. ROMERO A, Tora-Rocamora I, Bare M, Barata T, et al
    Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs.
    BMC Cancer. 2016;16:735.
    PubMed     Text format     Abstract available


  159. HONG R, Ma F, Zhang W, Yu X, et al
    53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
    BMC Cancer. 2016;16:725.
    PubMed     Text format     Abstract available


  160. OH K, Lee OY, Park Y, Seo MW, et al
    IL-1beta induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells.
    BMC Cancer. 2016;16:724.
    PubMed     Text format     Abstract available


  161. CORDINA-DUVERGER E, Truong T, Anger A, Sanchez M, et al
    Weight and weight changes throughout life and postmenopausal breast cancer risk: a case-control study in France.
    BMC Cancer. 2016;16:761.
    PubMed     Text format     Abstract available


  162. HADAD SM, Jordan LB, Roy PG, Purdie CA, et al
    A prospective comparison of ER, PR, Ki67 and gene expression in paired sequential core biopsies of primary, untreated breast cancer.
    BMC Cancer. 2016;16:745.
    PubMed     Text format     Abstract available


  163. MATSUMURA K, Nakata S, Taniguchi K, Ii H, et al
    Depletion of gamma-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation.
    BMC Cancer. 2016;16:748.
    PubMed     Text format     Abstract available


    January 2015
  164. TSENG CH
    Prolonged use of human insulin increases breast cancer risk in Taiwanese women with type 2 diabetes.
    BMC Cancer. 2015;15:846.
    PubMed     Text format     Abstract available


  165. KASTRATI I, Litosh VA, Zhao S, Alvarez M, et al
    A novel aspirin prodrug inhibits NFkappaB activity and breast cancer stem cell properties.
    BMC Cancer. 2015;15:845.
    PubMed     Text format     Abstract available


  166. LIU D, Deng Q, Sun L, Wang T, et al
    A Her2-let-7-beta2-AR circuit affects prognosis in patients with Her2-positive breast cancer.
    BMC Cancer. 2015;15:832.
    PubMed     Text format     Abstract available


  167. ATTIA YM, El-Abhar HS, Al Marzabani MM, Shouman SA, et al
    Targeting glycolysis by 3-bromopyruvate improves tamoxifen cytotoxicity of breast cancer cell lines.
    BMC Cancer. 2015;15:838.
    PubMed     Text format     Abstract available


  168. CHO KH, Yu SL, Cho do Y, Park CG, et al
    Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-beta1-induced breast cancer cell aggressiveness through downregulating HIF-1alpha expression.
    BMC Cancer. 2015;15:829.
    PubMed     Text format     Abstract available


  169. CHEN X, Zhu S, Fei X, Garfield DH, et al
    Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
    BMC Cancer. 2015;15:822.
    PubMed     Text format     Abstract available


  170. WERNER S, Stamm H, Pandjaitan M, Kemming D, et al
    Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells.
    BMC Cancer. 2015;15:896.
    PubMed     Text format     Abstract available


  171. PROVATOPOULOU X, Georgiou GP, Kalogera E, Kalles V, et al
    Serum irisin levels are lower in patients with breast cancer: association with disease diagnosis and tumor characteristics.
    BMC Cancer. 2015;15:898.
    PubMed     Text format     Abstract available


  172. GROGG A, Trippel M, Pfaltz K, Ladrach C, et al
    Androgen receptor status is highly conserved during tumor progression of breast cancer.
    BMC Cancer. 2015;15:872.
    PubMed     Text format     Abstract available


  173. SHIN A, Sandin S, Lof M, Margolis KL, et al
    Alcohol consumption, body mass index and breast cancer risk by hormone receptor status: Women' Lifestyle and Health Study.
    BMC Cancer. 2015;15:881.
    PubMed     Text format     Abstract available


  174. KARAVITES LC, Allu S, Khan SA, Kaiser K, et al
    Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study.
    BMC Cancer. 2015;15:878.
    PubMed     Text format     Abstract available


  175. JEON YW, Kang SH, Park MH, Lim W, et al
    Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    BMC Cancer. 2015;15:865.
    PubMed     Text format     Abstract available


  176. YANG L, Zhang XC, Yu SF, Zhu HQ, et al
    Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.
    BMC Cancer. 2015;15:917.
    PubMed     Text format     Abstract available


  177. WULANINGSIH W, Vahdaninia M, Rowley M, Holmberg L, et al
    Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis.
    BMC Cancer. 2015;15:913.
    PubMed     Text format     Abstract available


  178. FRANCIES FZ, Wainstein T, De Leeneer K, Cairns A, et al
    BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    BMC Cancer. 2015;15:912.
    PubMed     Text format     Abstract available


  179. KOO J, Cabarcas-Petroski S, Petrie JL, Diette N, et al
    Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein.
    BMC Cancer. 2015;15:905.
    PubMed     Text format     Abstract available


  180. ECCLES BK, Copson E, Maishman T, Abraham JE, et al
    Understanding of BRCA VUS genetic results by breast cancer specialists.
    BMC Cancer. 2015;15:936.
    PubMed     Text format     Abstract available


  181. GOSWAMI S, Sharma-Walia N
    Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.
    BMC Cancer. 2015;15:935.
    PubMed     Text format     Abstract available


  182. XU C, Wang Z, Cui R, He H, et al
    Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome.
    BMC Cancer. 2015;15:925.
    PubMed     Text format     Abstract available


  183. GOLDBERG M, Calderon-Margalit R, Paltiel O, Abu Ahmad W, et al
    Socioeconomic disparities in breast cancer incidence and survival among parous women: findings from a population-based cohort, 1964-2008.
    BMC Cancer. 2015;15:921.
    PubMed     Text format     Abstract available


  184. FANG C, Wei XM, Zeng XT, Wang FB, et al
    Aberrant GSTP1 promoter methylation is associated with increased risk and advanced stage of breast cancer: a meta-analysis of 19 case-control studies.
    BMC Cancer. 2015;15:920.
    PubMed     Text format     Abstract available


  185. HSU CY, Chang ZF, Lee HH
    Immunohistochemical evaluation of ROCK activation in invasive breast cancer.
    BMC Cancer. 2015;15:943.
    PubMed     Text format     Abstract available


  186. LIN CH, Chang CY, Lee KR, Lin HJ, et al
    Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway.
    BMC Cancer. 2015;15:958.
    PubMed     Text format     Abstract available


  187. PEI S, Yang X, Wang H, Zhang H, et al
    Plantamajoside, a potential anti-tumor herbal medicine inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of matrix metalloproteinase-9 and -2.
    BMC Cancer. 2015;15:965.
    PubMed     Text format     Abstract available


  188. SEIBOLD P, Schmezer P, Behrens S, Michailidou K, et al
    A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients.
    BMC Cancer. 2015;15:978.
    PubMed     Text format     Abstract available


  189. KIM S, Shore DL, Wilson LE, Sanniez EI, et al
    Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer.
    BMC Cancer. 2015;15:960.
    PubMed     Text format     Abstract available


  190. BORCH KB, Braaten T, Lund E, Weiderpass E, et al
    Physical activity before and after breast cancer diagnosis and survival - the Norwegian women and cancer cohort study.
    BMC Cancer. 2015;15:967.
    PubMed     Text format     Abstract available


  191. LEBOK P, Kopperschmidt V, Kluth M, Hube-Magg C, et al
    Partial PTEN deletion is linked to poor prognosis in breast cancer.
    BMC Cancer. 2015;15:963.
    PubMed     Text format     Abstract available


  192. SUPPAN C, Bjelic-Radisic V, La Garde M, Groselj-Strele A, et al
    Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.
    BMC Cancer. 2015;15:1027.
    PubMed     Text format     Abstract available


  193. STOLLEY MR, Sharp LK, Fantuzzi G, Arroyo C, et al
    Study design and protocol for moving forward: a weight loss intervention trial for African-American breast cancer survivors.
    BMC Cancer. 2015;15:1018.
    PubMed     Text format     Abstract available


  194. MITTICA G, Senetta R, Richiardi L, Ruda R, et al
    Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients.
    BMC Cancer. 2015;15:1021.
    PubMed     Text format     Abstract available


  195. LIANG C, Li L, Fraser CD, Ko A, et al
    The treatment patterns, efficacy, and safety of nab ((R))-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
    BMC Cancer. 2015;15:1019.
    PubMed     Text format     Abstract available


  196. HAMDAN D, Leboeuf C, Pereira C, Jourdan N, et al
    A digestive allergic reaction with hypereosinophilia imputable to docetaxel in a breast cancer patient: a case report.
    BMC Cancer. 2015;15:993.
    PubMed     Text format     Abstract available


  197. NAIPAL KA, Verkaik NS, Sanchez H, van Deurzen CH, et al
    Tumor slice culture system to assess drug response of primary breast cancer.
    BMC Cancer. 2016;16:78.
    PubMed     Text format     Abstract available


  198. NUZZO PV, Rubagotti A, Zinoli L, Salvi S, et al
    The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome.
    BMC Cancer. 2016;16:95.
    PubMed     Text format     Abstract available


  199. PAIVA CE, Siquelli FA, Santos HA, Costa MM, et al
    The Functionality Assessment Flowchart (FAF): a new simple and reliable method to measure performance status with a high percentage of agreement between observers.
    BMC Cancer. 2015;15:501.
    PubMed     Text format     Abstract available


  200. AN J, Lv J, Li A, Qiao J, et al
    Constitutive expression of Bcl-2 induces epithelial-Mesenchymal transition in mammary epithelial cells.
    BMC Cancer. 2015;15:476.
    PubMed     Text format     Abstract available


  201. BORGQUIST S, Zhou W, Jirstrom K, Amini RM, et al
    The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    BMC Cancer. 2015;15:468.
    PubMed     Text format     Abstract available


  202. ANASTASOV N, Hofig I, Radulovic V, Strobel S, et al
    A 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatment.
    BMC Cancer. 2015;15:466.
    PubMed     Text format     Abstract available


  203. TORRES-MEJIA G, Smith RA, Carranza-Flores Mde L, Bogart A, et al
    Radiographers supporting radiologists in the interpretation of screening mammography: a viable strategy to meet the shortage in the number of radiologists.
    BMC Cancer. 2015;15:410.
    PubMed     Text format     Abstract available


  204. TEH YC, Tan GH, Taib NA, Rahmat K, et al
    Opportunistic mammography screening provides effective detection rates in a limited resource healthcare system.
    BMC Cancer. 2015;15:405.
    PubMed     Text format     Abstract available


  205. HURST RE, Hauser PJ, You Y, Bailey-Downs LC, et al
    Identification of novel drugs to target dormant micrometastases.
    BMC Cancer. 2015;15:404.
    PubMed     Text format     Abstract available


  206. YAN B, Stantic M, Zobalova R, Bezawork-Geleta A, et al
    Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner.
    BMC Cancer. 2015;15:401.
    PubMed     Text format     Abstract available


  207. YAN M, Shield-Artin K, Byrne D, Deb S, et al
    Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
    BMC Cancer. 2015;15:506.
    PubMed     Text format     Abstract available


  208. FRAMARINO-DEI-MALATESTA M, Perrone G, Giancotti A, Ventriglia F, et al
    Epirubicin: a new entry in the list of fetal cardiotoxic drugs? Intrauterine death of one fetus in a twin pregnancy. Case report and review of literature.
    BMC Cancer. 2015;15:951.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: